Objective:To investigate the expression of platelet activating factor acetylhydrolase 1b catalytic subunit 3 (PAFAH1B3) in bladder cancer cells, and to explore the effects of PAFAH1B3 on proliferation, migration, and aerobic glycolysis in bladder cancer T24 cells and its mechanism.Methods:The relative expression of PAFAH1B3 in bladder cancer RT4, 5637, T24, J82T24 cells and human normal bladder epithelial SV-HUC-1 cells were detected using Western blotting. After culture, T24 cells were divided into a control group and a knockdown group based on treatment conditions. T24 cells were transfected with 50 nmol/L of negative control small interfering RNA (siRNA) or PAFAH1B3 siRNA, respectively. T24 cells with PAFAH1B3 knockdown were subsequently infected with an adenovirus vector overexpressing αB-crystallin ( CRYAB) at a multiplicity of infection of 50, and were designated as the overexpression group. The relative expression of PAFAH1B3 in T24 cells was detected using Western blotting. The cell survival rate, the number of colonies per unit field of view and the scratch closure rate of T24 cells were assessed using cell counting kit-8, colony formation assay and scratch assay, respectively. Glucose uptake, lactate production and adenosine triphosphate (ATP) levels of T24 cells were measured with corresponding commercial kits. The relative expression levels of glucose transporter 1 (GLUT1), hexokinase 2 (HK2), lactate dehydrogenase A (LDHA), CRYAB, phosphorylated phosphoinositide 3-kinase (p-PI3K) to PI3K and phosphorylated protein kinase B (p-Akt) to Akt were detected using Western blotting. Data were analyzed by an independent sample t test or one-way analysis of variance. Results:The relative expression levels of PAFAH1B3 protein in RT4, 5637, T24 and J82 cells (1.13±0.15, 1.40±0.10, 1.50±0.10, 0.77±0.13) were significantly higher than that in SV-HUC-1 cells (0.42±0.08) (all P<0.01). The relative expression levels of PAFAH1B3 protein in the knockdown group (0.22±0.08) was significantly lower than that in the control group (1.08±0.03) ( P<0.01). The cell survival rate, the number of colonies per unit field of view and the scratch closure rate in the knockdown group [(54.00±6.00)%, (104.00±8.00) cells, (42.00±3.00)%] were all lower than those in the control group [(96.00±3.00)%, (170.00±6.00) cells, (72.00±4.00)%] (all P<0.01). Glucose uptake, lactate production and ATP level in the knockdown group [(0.46±0.09) mg/ml, (22.67±2.67, 7.50±0.15) μmol/L] were lower than those in the control group [(1.21±0.11) mg/ml, (41.67±2.33, 18.00±2.00) μmol/L] (all P<0.01). The relative expression levels of GLUT1, HK2 and LDHA proteins in the knockdown group (0.31±0.04, 0.18±0.03, 0.47±0.07) were all lower than those in the control group (0.89±0.09, 0.97±0.04, 0.95±0.03) (all P<0.01). The relative expression of CRYAB, p-PI3K/PI3K and p-Akt/Akt proteins in the knockdown group (0.26±0.04, 0.44±0.03, 0.31±0.04) were all lower than those in the control group (0.99±0.05, 0.94±0.05, 0.99±0.06) (all P<0.01). The relative expression of CRYAB in the overexpression group (4.30±0.40) was higher than that in the knockdown group (0.94±0.05) ( P<0.01). The cell survival rate and the number of colonies per unit field of view in the overexpression group [(92.00±3.00)%, (172.00±8.00) cells] were all higher than those in the knockdown group [(46.00±3.00)%, (103.00±7.00) cells] (both P<0.01). Glucose uptake, lactate production and ATP level in the overexpression group [(1.25±0.06) mg/ml, (43.00±4.00, 21.00±2.00) μmol/L] were all higher than those in the knockdown group [(0.49±0.06) mg/ml, (19.00±3.00, 7.00±1.00) μmol/L] (all P<0.01). The relative expression levels of GLUT1, HK2 and LDHA proteins in the overexpression group (0.71±0.04, 0.98±0.04, 0.99±0.04) were higher than those in the knockdown group (0.26±0.03, 0.52±0.03, 0.21±0.02) (all P<0.01). The relative expression levels of p-PI3K/PI3K and p-Akt/Akt proteins in the overexpression group (0.77±0.03, 0.96±0.04) were all higher than those in the knockdown group (0.24±0.05, 0.18±0.03) (both P<0.01). Conclusions:PAFAH1B3 may promote the proliferation, migration and aerobic glycolysis of bladder cancer cells via regulation of the CRYAB/PI3K/Akt signaling pathway.

Objective To analyze the relationship between implant placement methods and the change of alveolar crest mucosal thickness under different gingival thickness.Methods A total of 98 patients with posterior tooth loss from June 2022 to December 2022 were selected,and a total of 120 implants were implanted.There were 90 samples in the thin gingiva group(gingiva thickness＜3 mm)and 30 samples in the thick gingiva group(gingiva thickness≥3 mm).For the thin gingival cases,three different surgical meth-ods were used for one-stage implantation.Group A(32 teeth)received ridge trimming before implantation.In group B,30 implants were placed under the bone.In group C,28 teeth used tent technique to analyze the vertical soft tissue thickness changes of alveolar crest before and 3～4 months after osseointegration.Results The thin gingival group was treated with three different treatments A,B and C.The gingival thickness increased from Ha(1.96±0.35)mm,Hb(1.89±0.42)mm,Hc(1.96±0.29)mm to H'a(2.88±0.23)mm,H'b(2.93±0.30)mm,H'c(2.65±0.22)mm,respectively.The alveolar crest vertical mucosal thickness of the three groups increased significantly(P＜0.05).The increase in group A and B(about 1 mm)was slightly higher than that in group C(about 0.6 mm),while there was no significant difference between the control group Hd(3.60±0.24)mm and H'd(3.36±0.47)mm(P＞0.05).In addition,the intraoperative gingival thickness measurements(Ha,Hb,Hc,Hd)were basically consistent with the CBCT imaging measurements(HA,HB,HC,HD),and there was no significant difference(P＞0.05).Conclusion Careful analysis of the vertical thickness of the alveolar crest to the mucosa before implant surgery and selection of different implantation methods can increase the vertical thickness of the alveolar crest to the appropriate position,thereby maintaining the stability of the bone around the implant and improving the success rate of the implant.

Objective To construct a uricase-deficient mouse model with stable inheritance using the CRISPR/Cas9 system,and evaluate its ability to simulate the disease characteristics of patients with hyperuricemia.Methods Double single guide RNAs(sgRNAs)were designed on both sides of exon 2～4 of the Uox gene.sgRNA and Cas9 mRNA for gene knockout were microinjected into the fertilized eggs of mice.After culture for 2～4 h,the embryos were transferred to surrogate mother mice to produce an F0 generation.Uox-knockout mice were identified by polymerase chain reaction and sequencing analysis.Positive mice were then mated with wild-type(WT)mice to produce an F1 generation,and heterozygous female and male F1 mice were then selected to obtain homozygous F2 mice.Serum and urine levels of uric acid,creatinine,and urea,and serum alanine aminotransferase(ALT)and aspartate aminotransferase(AST)levels were detected and compared between homozygous and wild-type mice.Pathological changes in kidney and liver tissues were observed by hematoxylin and eosin and Masson staining.Results Urine levels of serum uric acid(male:(4116.8±1928.1)μmol/L,P＜0.001;female:(2998.0±547.7)μmol/L,P＜0.01)and serum levels of uric acid(male:(478.4±114.6)μmol/L,P＜0.001;female:(507.7±129.6)μmol/L,P＜0.001),creatinine((91.8±55.6)μmol/L,P＜0.001),urea((28.6±13.9)mmol/L,P＜0.05),ALT((53.3±23.3)U/L,P＜0.01),and AST((203.3±70.3)U/L,P＜0.001)were significantly increased in Uox-/-mice compared with WT mice.Histopathological examination showed moderate hepatocyte degeneration in the liver,moderate-to-severe tubular cystic dilation,degeneration,and fibrosis in the kidney,glomerular hypertrophy and hyperplasia,small-vessel dilation and congestion,and infiltration of stromal monocytes and lymphocytes in Uox-/-mice.Conclusions We successfully established a homozygous uricase-deficient mouse strain using CRISPR/Cas9 technology,as a suitable animal model for research in the field of hyperuricemia.

Objective To construct a uricase-deficient mouse model with stable inheritance using the CRISPR/Cas9 system,and evaluate its ability to simulate the disease characteristics of patients with hyperuricemia.Methods Double single guide RNAs(sgRNAs)were designed on both sides of exon 2～4 of the Uox gene.sgRNA and Cas9 mRNA for gene knockout were microinjected into the fertilized eggs of mice.After culture for 2～4 h,the embryos were transferred to surrogate mother mice to produce an F0 generation.Uox-knockout mice were identified by polymerase chain reaction and sequencing analysis.Positive mice were then mated with wild-type(WT)mice to produce an F1 generation,and heterozygous female and male F1 mice were then selected to obtain homozygous F2 mice.Serum and urine levels of uric acid,creatinine,and urea,and serum alanine aminotransferase(ALT)and aspartate aminotransferase(AST)levels were detected and compared between homozygous and wild-type mice.Pathological changes in kidney and liver tissues were observed by hematoxylin and eosin and Masson staining.Results Urine levels of serum uric acid(male:(4116.8±1928.1)μmol/L,P＜0.001;female:(2998.0±547.7)μmol/L,P＜0.01)and serum levels of uric acid(male:(478.4±114.6)μmol/L,P＜0.001;female:(507.7±129.6)μmol/L,P＜0.001),creatinine((91.8±55.6)μmol/L,P＜0.001),urea((28.6±13.9)mmol/L,P＜0.05),ALT((53.3±23.3)U/L,P＜0.01),and AST((203.3±70.3)U/L,P＜0.001)were significantly increased in Uox-/-mice compared with WT mice.Histopathological examination showed moderate hepatocyte degeneration in the liver,moderate-to-severe tubular cystic dilation,degeneration,and fibrosis in the kidney,glomerular hypertrophy and hyperplasia,small-vessel dilation and congestion,and infiltration of stromal monocytes and lymphocytes in Uox-/-mice.Conclusions We successfully established a homozygous uricase-deficient mouse strain using CRISPR/Cas9 technology,as a suitable animal model for research in the field of hyperuricemia.

Objective To analyze the relationship between implant placement methods and the change of alveolar crest mucosal thickness under different gingival thickness.Methods A total of 98 patients with posterior tooth loss from June 2022 to December 2022 were selected,and a total of 120 implants were implanted.There were 90 samples in the thin gingiva group(gingiva thickness＜3 mm)and 30 samples in the thick gingiva group(gingiva thickness≥3 mm).For the thin gingival cases,three different surgical meth-ods were used for one-stage implantation.Group A(32 teeth)received ridge trimming before implantation.In group B,30 implants were placed under the bone.In group C,28 teeth used tent technique to analyze the vertical soft tissue thickness changes of alveolar crest before and 3～4 months after osseointegration.Results The thin gingival group was treated with three different treatments A,B and C.The gingival thickness increased from Ha(1.96±0.35)mm,Hb(1.89±0.42)mm,Hc(1.96±0.29)mm to H'a(2.88±0.23)mm,H'b(2.93±0.30)mm,H'c(2.65±0.22)mm,respectively.The alveolar crest vertical mucosal thickness of the three groups increased significantly(P＜0.05).The increase in group A and B(about 1 mm)was slightly higher than that in group C(about 0.6 mm),while there was no significant difference between the control group Hd(3.60±0.24)mm and H'd(3.36±0.47)mm(P＞0.05).In addition,the intraoperative gingival thickness measurements(Ha,Hb,Hc,Hd)were basically consistent with the CBCT imaging measurements(HA,HB,HC,HD),and there was no significant difference(P＞0.05).Conclusion Careful analysis of the vertical thickness of the alveolar crest to the mucosa before implant surgery and selection of different implantation methods can increase the vertical thickness of the alveolar crest to the appropriate position,thereby maintaining the stability of the bone around the implant and improving the success rate of the implant.

Objective This study aimed to identify PAX9 variants in non-syndromic tooth agenesis families of Chi-na,as well as to analyze the genotype-phenotype of non-syndromic tooth agenesis caused by PAX9 variants,which can provide a basis for the genetic diagnosis of tooth agenesis.Methods We collected the data of 44 patients with non-syn-dromic oligodontia who underwent treatment at Stomatological Hospital of Hebei Medical University between 2018 and 2023.Whole-exome sequencing was performed on the peripheral blood of the proband and its core family members,and the variants were verified by Sanger sequencing.Pathogenicity analysis and function prediction of the variants were per-formed using bioinformatics tools.The correlation between the genotype of PAX9 variant and its corresponding pheno-type was examined by reviewing 55 publications retrieved from PubMed.The studies involved 232 tooth agenesis pa-tients with PAX9 variants.Results A novel PAX9 c.447delG(p.Pro150Argfs*62)and a reported PAX9 c.406C>T(p.Gln136*)were identified in two Chinese families.Through bioinformatics analysis and three-dimensional structural mod-eling,we postulated that the frameshift variant was pathogenic.The outcome was the premature cessation of PAX9 pro-tein,which caused severe structural and functional deficiencies.Summarizing the PAX9 genotype-phenotype relationship revealed that patients carrying the PAX9 variant commonly led to loss of the second molars.Conclusion We identified the novel PAX9 c.447delG(p.Pro150Argfs*62)in a Chinese family of non-syndromic oligodontia,expanding the known variant spectrum of PAX9.The most susceptible tooth position for PAX9 variants of tooth agenesis was the second mo-lars and the deciduous molars during the deciduous dentition.

Objective:To evaluate the efficacy and safety of Chinese medicine Jianpi Antai formula in infertile women undergoing in vitro fertilization-embryo transfer(IVF-ET).Methods:A total of 300 infertile women who underwent 2 frozen embryo transfer procedures at the Reproductive Medicine Center,Sir Run Run Shaw Hospital were included in the study.The participants were randomly divided into study group and control group.The study group received routine medication plus the Jianpi Antai formula during the period of embryo transfer,while the control group received routine medication only.The general condition,embryo implantation rate,clinical pregnancy rate,live birth rate,and the blood routine and liver and kidney function were evaluated and compared between two groups.Results:There were 277 cases who completed the study,including 134 in the study group and 143 in the control group.The embryo implantation rate(68.7%vs.55.9%),the clinical pregnancy rate(56.7%vs.44.8%)and the live birth rate(50.7%vs.37.8%)in the study group were all higher than those in the control group(all P＜0.05).Subgroup analysis revealed that in patients of advanced age(≥35 years)and those with decreased ovarian reserve function(anti-Müllerian hormone＜1.68 ng/mL),the embryo implantation rate,clinical pregnancy rate,and live birth rate in the study group were all higher than those in the control group(all P＜0.05).During the follow-up period,there were no abnormalities in the basic vital signs of both groups,and no adverse events were reported.Conclusion:Jianpi Antai formula can safely improve the embryo implantation rate in infertile women undergoing IVF-ET,reduce the embryo miscarriage rate,increase the live birth rate as well as improve the clinical outcomes.

Melatonin receptor 1B (MT2, encoded by the MTNR1B gene), a high-affinity receptor for melatonin, is associated with glucose homeostasis including glucose uptake and transport. The rs10830963 variant in the MTNR1B gene is linked to glucose metabolism disorders including gestational diabetes mellitus (GDM); however, the relationship between MT2-mediated melatonin signaling and a high birth weight of GDM infants from maternal glucose abnormality remains poorly understood. This article aims to investigate the relationship between rs10830963 variants and GDM development, as well as the effects of MT2 receptor on glucose uptake and transport in trophoblasts. TaqMan-MGB (minor groove binder) probe quantitative real-time polymerase chain reaction (qPCR) assays were used for rs10930963 genotyping. MT2 expression in the placenta of GDM and normal pregnant women was detected by immunofluorescence, western blot, and qPCR. The relationship between MT2 and glucose transporters (GLUTs) or peroxisome proliferator-activated receptor γ (PPARγ) was established by western blot, and glucose consumption of trophoblasts was measured by a glucose assay kit. The results showed that the genotype and allele frequencies of rs10830963 were significantly different between GDM and normal pregnant women (P<0.05). The fasting, 1-h and 2-h plasma glucose levels of G-allele carriers were significantly higher than those of C-allele carriers (P<0.05). Besides, the protein and messenger RNA (mRNA) expression of MT2 in the placenta of GDM was significantly higher than that of normal pregnant women (P<0.05). Melatonin could stimulate glucose uptake and GLUT4 and PPARγ protein expression in trophoblasts, which could be attenuated by MT2 receptor knockdown. In conclusion, the rs10830963 variant was associated with an increased risk of GDM. The MT2 receptor is essential for melatonin to raise glucose uptake and transport, which may be mediated by PPARγ.
Female ; Humans ; Pregnancy ; Blood Glucose/metabolism* ; Diabetes, Gestational/metabolism* ; Glucose/metabolism* ; Melatonin/metabolism* ; Polymorphism, Genetic ; PPAR gamma ; Receptor, Melatonin, MT2/genetics*

Based on a research on judicial cases concerning the authenticity of electronic medical records in the past three years, the authors encountered judicial dilemmas in judicial practice. The challenges arise due to the special manifestations of electronic medical records, unclear and disputable criteria for the authenticity of electronic medical records, low application level of electronic medical records identification, and inconsistent responsibility attribution. In order to effectively apply the electronic medical record system, it is recommend to promote pre-litigation prevention by unifying the construction standards of the computerized patient record system, strengthening hospital electronic medical record management and entrusting third-party storage to ensure the evidential weight. In addition, it is necessary to establish standards for authenticity of medical records, improve the electronic medical record forensic identification system and clarify the attribution of the responsibility for untrue medical records, so as to improve the handling of such medical damage cases during litigation.

With the rapid development of " Internet+ healthcare" , medical data has gained an ever important role. How to determine the reasonable use boundary of medical data and leverage its supporting role, has grown an urgent problem to be solved. The authors analyzed the characteristics of medical data, and held that medical data is not equivalent to information, as it does not have the characteristics of legal objects in nature. In addition, it lacks originality. Therefore it is difficult to protect through the existing rights system. However, due to its property interest and personality, the authors tried to establish a new right for protection. In the construction of such medical data right, the authors claimed that patients should be the subject of the right, and medical institutions can appropriately restrict the freedom of patients′ through reasonable use rules and legal licensing system. In this way, we can not only promote medical data sharing and the development of social health, but also fully protect the legitimate rights and interests of patients.